Loading...
Docoh

Black Diamond Therapeutics (BDTX)

Filed: 10 Jan 22, 10:46am

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 10, 2022

 

 

 

Black Diamond Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware001-3920081-4254660
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)

 

One Main Street, 10th Floor  
Cambridge, MA 02142
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: 617-252-0848

 

Not Applicable
(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareBDTXThe Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01.Other Events.

 

BDTX-1535

 

On January 10, 2022, Black Diamond Therapeutics, Inc. (the “Company”) announced that the US Food and Drug Administration had allowed its Investigational New Drug application for BDTX-1535. The Company expects to initiate the Phase 1 study of BDTX-1535 in the first quarter of 2022 and expects to provide a clinical update in the second half of 2023.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

January 10, 2022BLACK DIAMOND THERAPEUTICS, INC.
   
 By:/s/ Brent Hatzis-Schoch
  Name:   Brent Hatzis-Schoch
  Title:     Chief Operating Officer and General Counsel